Author:
Kolbinger Frank,Di Padova Franco,Deodhar Atul,Hawkes Jason E.,Huppertz Christine,Kuiper Torsten,McInnes Iain B.,Ritchlin Christopher T.,Rosmarin David,Schett Georg,Carballido José M.,Häusermann Peter,Calonder Claudio,Vogel Beate,Rondeau Jean-Michel,Bruin Gerard
Funder
GlaxoSmithKline
Janssen Pharmaceuticals
Novartis
UCB
Gilead Sciences
Celgene
AstraZeneca
Boehringer Ingelheim
Eli Lilly and Company
Pfizer
Bristol-Myers Squibb
Novartis Pharmaceuticals Corporation
Subject
Pharmacology (medical),Pharmacology
Reference128 articles.
1. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F;Adams;Frontiers in Immunology,2020
2. Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies;Augustin;Journal of the European Academy of Dermatology and Venereology,2020
3. Secukinumab dosing every two weeks demonstrated superior efficacy compared to dosing every four weeks in psoriasis patients weighing 90 kg or more;Augustin,2020
4. Continued treatment with secukinumab is associated with high retention or regain of response;Augustin;The British Journal of Dermatology,2020
5. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study;Baeten;Annals of the Rheumatic Diseases,2018
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献